Neogenomics Class Action Lawsuit NEO | Deadline February 6, 2023

Announcement! On behalf of all investors who bought or otherwise acquired Neogenomics Inc. (Neogenomics Class Action Lawsuit) common stock between February 27, 2020, and April 26, 2022, have an opportunity to join the NEO lawsuit.

TO LEARN MORE ABOUT THE NEO CLASS ACTION LAWSUIT, CLICK HERE

According to the Neo lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:

(i) In order to position the Company as a “one-stop shop” for pathologists and give NeoGenomics “a competitive advantage,” defendants falsely stated to investors that it had a “comprehensive menu” of cancer tests with “every kind of testing modality that you can use for cancer, including some of the fast-growing new ones, like next-generation sequencing”; and

(ii) In addition to praising the Company’s “robust Compliance Program to ensure compliance with the myriad laws, regulations, and governmental guidance applicable to our business,” defendants claimed that NeoGenomics could “leverage” the ostensibly “fixed cost” structure of its business to improve profitability as revenue increased.

If you suffered a loss in NEO Lawsuit, you have until February 6, 2023, to request that the Court appoint you as the lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.